Welcome to our dedicated page for Surgery Partners SEC filings (Ticker: SGRY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Surgery Partners, Inc. (SGRY) SEC filings page provides access to the company’s regulatory disclosures as a Nasdaq-listed healthcare services company focused on short-stay and outpatient surgical care. Through these filings, investors can review detailed information about the business, its capital structure, governance and financial performance.
Surgery Partners’ annual reports on Form 10-K and quarterly reports on Form 10-Q describe its outpatient delivery model, the composition of its network of ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities, and the risks associated with operating in the healthcare sector. These reports also present audited and interim financial statements, management’s discussion and analysis, and risk factor disclosures related to reimbursement, regulation, physician relationships, supply chain, cybersecurity and indebtedness.
Current reports on Form 8-K highlight material events such as debt issuances, credit agreement amendments, earnings releases and leadership changes. For example, recent 8-K filings describe the issuance of additional 7.250% senior notes due 2032 by subsidiary Surgery Center Holdings, Inc., the execution of a second amendment to the company’s credit agreement establishing refinancing term loans and revolving credit commitments, and the announcement of quarterly financial results. Other 8-Ks report board and executive transitions, including resignations, appointments and related employment agreements.
Filings related to capital markets activity, such as indentures for senior notes and amendments to credit facilities, provide insight into interest rates, maturities, guarantees and covenants that shape Surgery Partners’ financial obligations. These documents are important for understanding leverage, refinancing plans and the structure of obligations at the operating subsidiary level.
On this page, AI-powered tools can help summarize lengthy filings, highlight key terms in debt agreements, and clarify the implications of earnings releases and non-GAAP measures like Adjusted EBITDA. Investors can use these summaries to quickly identify items such as revenue trends, same-facility performance, liquidity metrics, leverage ratios and governance changes, while still having direct access to the full text of Forms 10-K, 10-Q, 8-K and related exhibits filed with the SEC.
Surgery Partners, Inc. (SGRY) Rule 144 notice shows an insider intends to sell 25,000 newly acquired common shares through UBS Financial Services on
The filing also lists multiple recent sales by Wayne DeVeydt totaling numerous transactions between
Surgery Partners, Inc. (SGRY) Form 144 notice reports a planned sale of 18,134 common shares through UBS on 09/29/2025 with an aggregate market value of $399,822. The filer states these shares were acquired the same day via an equity option exercise, and the proposed sale will be executed on NASDAQ. The filing lists extensive insider selling by Wayne DeVeydt over the prior three months totaling 719,604 shares sold across multiple dates, generating cumulative gross proceeds reported in the filing. The company has 128,209,410 shares outstanding, which provides context for the scale of these transactions relative to the float.
Surgery Partners, Inc. (SGRY) Form 144 shows a proposed sale of 5,627 common shares through UBS Financial Services on September 26, 2025. The shares were recorded as acquired the same day via equity compensation and an equity option exercise. The reported aggregate market value for the proposed sale is $123,794 and the issuer has 128,209,410 shares outstanding. The filing also lists multiple recent open-market sales by Wayne DeVeydt totaling 713,977 shares sold across dates from August 21, 2025 through September 23, 2025 with individual gross proceeds reported for each lot.
Surgery Partners, Inc. (SGRY) Form 144 reports a proposed sale of 25,000 common shares to be executed on 09/23/2025 through UBS Financial Services (Weehawken, NJ). The filing states these shares were acquired on 09/23/2025 as equity compensation through an equity option exercise from Surgery Partners, Inc. The notice is submitted under Rule 144 and includes the seller's representation that they are not aware of any undisclosed material adverse information about the issuer. The filing also discloses numerous recent open-market sales by the same person, dated between 08/21/2025 and 09/22/2025, across multiple transactions.
Surgery Partners, Inc. (SGRY) Rule 144 notice discloses a proposed sale of 50,000 common shares through UBS Financial Services (Nasdaq) with an aggregate market value of $1,092,666 and an approximate sale date of 09/22/2025. The shares were acquired and paid for on 09/22/2025 via an equity option exercise from Surgery Partners, Inc. The filing also lists multiple recent open-market sales by Wayne DeVeydt totaling large share blocks between 08/21/2025 and 09/19/2025, including transactions of 100,000, 150,000, and other lots with combined gross proceeds in the multi-million dollar range. The filer affirms no undisclosed material adverse information.
Surgery Partners, Inc. (SGRY) Form 144 notice reports an intended sale of 10,613 common shares through UBS Financial Services on NASDAQ with an aggregate market value of $234,547.30. The securities were acquired the same day as equity compensation via an equity option exercise. The filer reports numerous recent open-market sales by Wayne DeVeydt totaling multiple transactions between August and September 2025, including sales of 100,000 and 150,000 share lots. The filing affirms the seller does not possess undisclosed material adverse information. The reported number of shares outstanding is 128,209,410, providing context for the relative scale of the transactions.
Surgery Partners, Inc. (SGRY) has submitted a Form 144 reporting a proposed sale of 150,000 common shares through UBS Financial Services with an aggregate market value of $3,294,454.97. The shares were acquired on 09/18/2025 via an equity option exercise from Surgery Partners, Inc., and the planned sale is listed for 09/18/2025 on NASDAQ. The filing also discloses multiple recent sales by Wayne DeVeydt between 08/21/2025 and 09/17/2025, including transactions of 100,000 shares on 08/21/2025 and 09/11/2025 and several smaller sales, each with stated gross proceeds. The notice includes the signers representation that they are not aware of undisclosed material adverse information about the issuer.
Surgery Partners, Inc. (SGRY) Form 144 reports a proposed sale of 85,785 common shares through UBS Financial Services with an aggregate market value of $1,873,875, with an approximate sale date of 09/17/2025 on NASDAQ. The shares were acquired on 09/17/2025 by equity compensation from Surgery Partners, Inc., with payment described as an equity option exercise. The filing also discloses multiple recent open-market sales by Wayne DeVeydt totaling 392,579 shares between 08/21/2025 and 09/16/2025 generating aggregate gross proceeds reported in the table. The signee represents no undisclosed material adverse information.
Surgery Partners, Inc. (SGRY) Form 144 shows a proposed sale of 25,000 common shares through UBS on 09/16/2025, with an aggregate market value reported as $541,517.60. The shares were acquired on 09/16/2025 via equity compensation and the payment/nature is listed as an equity option exercise. The filing also discloses that the same account (Wayne DeVeydt) sold a total of 367,579 common shares in the prior three months for aggregate gross proceeds of $8,267,200. The filing lists 128,209,410 shares outstanding, and the planned sale is to occur on the NASDAQ through UBS Financial Services.
Surgery Partners, Inc. reported that Harrison R. Bane, its National Group President, has decided to resign from his current role, effective October 3, 2025. The company states that Mr. Bane’s resignation is not due to any disagreement with Surgery Partners on operations, policies, or practices, indicating this is a personal or career decision rather than a dispute with the company.
FAQ
What is the current stock price of Surgery Partners (SGRY)?
What is the market cap of Surgery Partners (SGRY)?
